Retroviral protein transfer: Falling apart to make an impact

Current Gene Therapy

Volumn 12, Issue 5, 2012, Pages 389-409

  Maetzig, Tobias ^a   Baum, Christopher ^a   Schambach, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Human Immunodeficiency Virus; Mouse Leukemia Virus; Retroviral imaging; Retroviral protein transfer; Retroviral vector; Virus like particle

Indexed keywords

LENTIVIRUS VECTOR; MESSENGER RNA; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; VIRUS PROTEIN;

LIFE CYCLE; NONHUMAN; PROTEIN TRANSPORT; RETROVIRUS; REVIEW; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS PARTICLE;

ANIMALS; CELL-PENETRATING PEPTIDES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; MOLECULAR IMAGING; PLASMIDS; RETROVIRIDAE; RNA, MESSENGER; RNA, VIRAL; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS; MURINE LEUKEMIA VIRUS;

EID: 84867004626     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802762581     Document Type: Review

References (205)

1. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012; 13: 214-22.
2. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010; 8: 55-67.
3. Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol R 2002; 66: 396-406.
4. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3: 388-98.
5. Frankel AD, Young JAT. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998; 67: 1-25.
6. Grüter P, Tabernero C, von Kobbe C, et al. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol Cell 1998; 1: 649-59.
7. Bogerd HP, Echarri A, Ross TM, Cullen BR. Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J Virol 1998; 72: 8627-35.
8. Malim MH, Hauber J, Le SY, et al. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338: 254-7.
9. LeBlanc JJ, Uddowla S, Abraham B, Clatterbuck S, Beemon KL. Tap and Dbp5, but not Gag, are involved in DR-mediated nuclear export of unspliced Rous sarcoma virus RNA. Virology 2007; 363: 376-86.
10. Zychlinski D, Erkelenz S, Melhorn V, et al. Limited complementarity between U1 snRNA and a retroviral 5' splice site permits its attenuation via RNA secondary structure. Nucleic Acids Res 2009; 37: 7429-40.
11. Kraunus J, Zychlinski D, Heise T, et al. Murine Leukemia Virus Regulates Alternative Splicing through Sequences Upstream of the 5' Splice Site. J Biol Chem 2006; 281: 37381-90.
12. Shehu-Xhilaga M, Crowe SM, Mak J. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol 2001; 75: 1834-41.
13. Park J, Morrow CD. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol 1991; 65: 5111-7.
14. Yoshinaka Y, Katoh I, Copeland T, Oroszlan S. Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci USA 1985; 82: 1618-22.
15. Jacks T, Power M, Masiarz F, et al. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331: 280-3.
16. Felsenstein KM, Goff SP. Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol 1988; 62: 2179-82.
17. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71: 5871-7.
18. Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr Gene Ther 2008; 8: 449-60.
19. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5: 387-98.
20. Anliker B, Abel T, Kneissl S, et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010; 7: 929-35.
21. Suzuki Y, Craigie R. The road to chromatin-nuclear entry of retroviruses. Nat Rev Microbiol 2007; 5: 187-96.
22. Schultz AM, Rein A. Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J Virol 1989; 63: 2370-3.
23. Rein A, McClure MR, Rice NR, Luftig RB, Schultz AM. Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc Natl Acad Sci USA 1986; 83: 7246-50.
24. Andrawiss M, Takeuchi Y, Hewlett L, Collins M. Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association. J Virol 2003; 77: 11651-60.
25. Göttlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 5781-5.
26. Valle-Casuso JC, Di Nunzio F, Yang Y, et al. TNPO3 is Required for HIV-1 Replication After Nuclear Import but Prior to Integration and Binds the HIV-1 Core. J Virol 2012; 86: 5931-6.
27. Schaller T, Ocwieja KE, Rasaiyaah J, et al. HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency. PLoS Pathog 2011; 7: e1002439.
28. Matreyek KA, Engelman A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol 2011; 85: 7818-27.
29. Auerbach MR, Brown KR, Kaplan A, de Las Nueces D, Singh IR. A small loop in the capsid protein of Moloney murine leukemia virus controls assembly of spherical cores. J Virol 2006; 80: 2884-93.
30. Alin K, Goff SP. Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology 1996; 222: 339-51.
31. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319: 921-6.
32. König R, Zhou Y, Elleder D, et al. Global analysis of hostpathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
33. Galla M, Will E, Kraunus J, Chen L, Baum C. Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 2004; 16: 309-15.
34. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010; 107: 7805-10.
35. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005; 42: 259-77.
36. Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci USA 2011; 108: 16998-7003.
37. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18: 537-45.
38. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1: 5-14.
39. Schambach A, Mueller D, Galla M, et al. Overcoming promoter competition in packaging cells improves production of selfinactivating retroviral vectors. Gene Ther 2006; 13: 1524-33.
40. Naldini L, Blömer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-8.
41. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of hightiter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-6.
42. Suerth JD, Maetzig T, Galla M, Baum C, Schambach A. Selfinactivating alpharetroviral vectors with a split-packaging design. J Virol 2010; 84: 6626-35.
43. Heinkelein M, Dressler M, Jármy G, et al. Improved primate foamy virus vectors and packaging constructs. J Virol 2002; 76: 3774-83.
44. Yu SF, Von Rüden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-8.
45. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-80.
46. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-25.
47. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-28.
48. Wagner R, Graf M, Bieler K, et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403-13.
49. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of betaglobin gene therapy for beta-thalassemia. Ann NY Acad Sci 2005; 1054: 308-16.
50. Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. ASH Education Program Book 2010; 2010: 445-50.
51. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-71.
52. Schaeffer E, Geleziunas R, Greene WC. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001; 75: 2993-3000.
53. Campbell EM, Hope TJ. Live cell imaging of the HIV-1 life cycle. Trends Microbiol 2008; 16: 580-7.
54. Danielson CM, Hope TJ. Imaging of HIV/host protein interactions. Curr Top Microbiol Immunol. 2009: 103-23.
55. Paxton W, Connor R, Landau N. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993; 67: 7229-37.
56. Kondo E, Gottlinger HG. A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996; 70: 159-64.
57. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. Human immunodeficiency virus type 1 modified to package simian immunodeficiency virus vpx efficiently infects macrophages and dendritic cells. J Virol 2011; 85: 6263-74.
58. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002; 20: 1151-4.
59. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009; 137: 433-44.
60. Lampe M, Briggs JAG, Endress T, et al. Double-labelled HIV-1 particles for study of virus-cell interaction. Virology 2007; 360: 92-104.
61. Green LA, Liu Y, He JJ. Inhibition of HIV-1 Infection and Replication by Enhancing Viral Incorporation of Innate Anti-HIV-1 Protein A3G. J Biol Chem 2009; 284: 13363-72.
62. Pereira CF, Ellenberg PC, Jones KL, et al. Labeling of multiple HIV-1 proteins with the biarsenical-tetracysteine system. PloS One 2011; 6: e17016.
63. Eckhardt M, Anders M, Muranyi W, et al. A SNAP-Tagged Derivative of HIV-1-A Versatile Tool to Study Virus-Cell Interactions. PloS One 2011; 6: e22007.
64. McDonald D, Vodicka MA, Lucero G, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002; 159: 441-52.
65. Müller B, Daecke J, Fackler OT, et al. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004; 78: 10803-13.
66. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001; 75: 3626-35.
67. Koch P, Lampe M, Godinez WJ, et al. Visualizing fusion of pseudotyped HIV-1 particles in real time by live cell microscopy. Retrovirology 2009; 6: 84.
68. Markosyan RM, Cohen FS, Melikyan GB. Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell 2005; 16: 5502-13.
69. Sherer NM, Lehmann MJ, Jimenez-Soto LF, et al. Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 2003; 4: 785-801.
70. Martin BR, Giepmans BNG, Adams SR, Tsien RY. Mammalian cell-based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity. Nat Biotechnol 2005; 23: 1308-14.
71. Griffin BA, Adams SR, Tsien RY. Specific covalent labeling of recombinant protein molecules inside live cells. Science 1998; 281: 269-72.
72. Stroffekova K, Proenza C, Beam KG. The protein-labeling reagent FLASH-EDT 2 binds not only to CCXXCC motifs but also nonspecifically to endogenous cysteine-rich proteins. Pflug Arch Eur J Phy 2001; 442: 859-66.
73. Adams SR, Campbell RE, Gross LA, et al. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc 2002; 124: 6063-76.
74. Gousset K, Ablan SD, Coren LV, et al. Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog 2008; 4: e1000015.
75. Turville SG, Aravantinou M, Stössel H, Romani N, Robbiani M. Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods 2007; 5: 75-85.
76. Arhel N, Genovesio A, Kim KA, et al. Quantitative fourdimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods 2006; 3: 817-24.
77. Lelek M, Di Nunzio F, Henriques R, et al. Superresolution imaging of HIV in infected cells with FlAsH-PALM. Proc Natl Acad Sci USA 2012.
78. Keppler A, Pick H, Arrivoli C, Vogel H, Johnsson K. Labeling of fusion proteins with synthetic fluorophores in live cells. Proc Natl Acad Sci USA 2004; 101: 9955-9.
79. Keppler A, Gendreizig S, Gronemeyer T, et al. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 2002; 21: 86-9.
80. Forshey BM, Von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002; 76: 5667-77.
81. Jun S, Ke D, Debiec K, et al. Direct Visualization of HIV-1 with Correlative Live-Cell Microscopy and Cryo-Electron Tomography. Structure 2011; 19: 1573-81.
82. Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci USA 2011; 108: 9975-80.
83. Arhel NJ, Souquere-Besse S, Munier S, et al. HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. Embo J 2007; 26: 3025-37.
84. Galla M, Schambach A, Falk CS, et al. Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011; 39: 7147-60.
85. Belshan M, Schweitzer CJ, Donnellan MR, Lu R, Engelman A. In vivo biotinylation and capture of HIV-1 matrix and integrase proteins. J Virol Methods 2009; 159: 178-84.
86. Belshan M, Matthews JM, Madson CJ. Replication of biotinylated human immunodeficiency viruses. J Virol Methods 2010; 171: 299-302.
87. Hermida-Matsumoto L, Resh MD. Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging. J Virol 2000; 74: 8670-9.
88. Sandefur S, Varthakavi V, Spearman P. The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J Virol 1998; 72: 2723-32.
89. Erlwein O, Buchholz CJ, Schnierle BS. The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol 2003; 84: 369-73.
90. Carr J, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 1999; 265: 319-29.
91. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007; 81: 1000-12.
92. Jin J, Li F, Mothes W. Viral determinants of polarized assembly for the murine leukemia virus. J Virol 2011; 85: 7672-82.
93. Jin J, Sherer NM, Heidecker G, Derse D, Mothes W. Assembly of the murine leukemia virus is directed towards sites of cell-cell contact. PLoS Biol 2009; 7: e1000163.
94. Sherer NM, Lehmann MJ, Jimenez-Soto LF, et al. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat Cell Biol 2007; 9: 310-5.
95. Masuda M, Kakushima N, Wilt SG, et al. Analysis of receptor usage by ecotropic murine retroviruses, using green fluorescent protein-tagged cationic amino acid transporters. J Virol 1999; 73: 8623-9.
96. Lehmann MJ, Sherer NM, Marks CB, Pypaert M, Mothes W. Actin-and myosin-driven movement of viruses along filopodia precedes their entry into cells. J Cell Biol 2005; 170: 317-25.
97. Voelkel C, Galla M, Dannhauser P, et al. Pseudotype-independent non-specific uptake of gammaretroviral and lentiviral particles in human cells. Hum Gene Ther 2011; 23: 274-86.
98. Sharma S, Miyanohara A, Friedmann T. Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol 2000; 74: 10790-5.
99. Sharma S, Murai F, Miyanohara A, Friedmann T. Noninfectious virus-like particles produced by Moloney murine leukemia virusbased retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc Natl Acad Sci USA 1997; 94: 10803-8.
100. Pizzato M, Blair E, Fling M, et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther 2001; 8: 1088-96.
101. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. Cell surface heparan sulfate is a receptor for attachment of envelope proteinfree retrovirus-like particles and VSV-G pseudotyped MLVderived retrovirus vectors to target cells. Mol Ther 2002; 5: 538-46.
102. Pizzato M, Marlow SA, Blair ED, Takeuchi Y. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol 1999; 73: 8599-611.
103. Beer C, Andersen DS, Rojek A, Pedersen L. Caveola-dependent endocytic entry of amphotropic murine leukemia virus. J Virol 2005; 79: 10776-87.
104. Katen LJ, Januszeski MM, Anderson WF, Hasenkrug KJ, Evans LH. Infectious entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an endocytic pathway. J Virol 2001; 75: 5018-26.
105. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55: 1179-88.
106. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
107. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci 1991; 88: 1864-8.
108. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. J Biol Chem 2001; 276: 5836-40.
109. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-50.
110. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
111. Chugh A, Eudes F, Shim YS. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells. IUBMB Life 2010; 62: 183-93.
112. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
113. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
114. van den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotech 2011.
115. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. Aaps J 2009; 11: 13-22.
116. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009; 27: 567-71.
117. Münst B, Patsch C, Edenhofer F. Engineering cell-permeable protein. J Vis Exp 2009; 43: e1627.
118. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 2011; 29: 6191-218.
119. Goulder PJR, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412: 334-8.
120. Leslie A, Pfafferott K, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10: 282-9.
121. Frost SDW, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102: 18514-9.
122. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2009; 10: 11-23.
123. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
124. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-41.
125. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996; 70: 3724-33.
126. Desrosiers RC, Lifson JD, Gibbs JS, et al. Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 1998; 72: 1431-7.
127. Berkhout B, Verhoef K, van Wamel JLB, Back NKT. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 1999; 73: 1138-45.
128. Sawai ET, Hamza MS, Ye M, Shaw KES, Luciw PA. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol 2000; 74: 2038-45.
129. Gundlach BR, Lewis MG, Sopper S, et al. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol 2000; 74: 3537-42.
130. Marzio G, Verhoef K, Vink M, Berkhout B. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci USA 2001; 98: 6342-7.
131. Zhou X, Vink M, Berkhout B, Das A. Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control. Retrovirology 2006; 3: 82.
132. Das AT, Baldwin CE, Vink M, Berkhout B. Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry. J Virol 2005; 79: 3855-8.
133. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007; 18: 546-56.
134. Hoxie JA. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010; 61: 135-52.
135. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Ann Rev Immunol 2009; 28: 413-44.
136. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008; 455: 109-13.
137. Zhu P, Liu J, Bess J, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441: 847-52.
138. Moore PL, Crooks ET, Porter L, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80: 2515-28.
139. Crooks ET, Moore PL, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007; 366: 245-62.
140. Crooks ET, Tong T, Osawa K, Binley JM. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 2011; 85: 5825-39.
141. Johnson MC. Mechanisms for Env glycoprotein acquisition by retroviruses. AIDS Res Hum Retrov 2011; 27: 239-47.
142. Gheysen D, Jacobs E, de Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59: 103-12.
143. Overton HA, Fujii Y, Price IR, Jones IM. The protease and gag gene products of the human immunodeficiency virus: Authentic cleavage and post-translational modification in an insect cell expression system. Virology 1989; 170: 107-16.
144. Royer M, Hong S, Gay B, Cerutti M, Boulanger P. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 1992; 66: 3230-5.
145. Luo L, Li Y, Kang CY. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells. Virology 1990; 179: 874-80.
146. Kräusslich HG, Ochsenbauer C, Traenckner AM, et al. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 1993; 192: 605-17.
147. McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007; 358: 334-46.
148. Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993; 262: 1448-51.
149. Buonaguro L, Racioppi L, Tornesello M, et al. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antivir Res 2002; 54: 189-201.
150. Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retrov 2000; 16: 273-82.
151. Kuate S, Stahl-Hennig C, Stoiber H, et al. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology 2006; 351: 133-44.
152. Buseyne F, Le Gall S, Boccaccio C, et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001; 7: 344-9.
153. Marsac D, Loirat D, Petit C, Schwartz O, Michel ML. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J Virol 2002; 76: 7544-53.
154. Donelly JJ, Liu MA, Ulmer JB. Antigen presentation and DNA vaccines. Am J Resp Crit Care 2000; 162: S190-S193.
155. Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999; 163: 4721-7.
156. Grgacic EVL, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40: 60-5.
157. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Rev Nanomed Nanobiotechnol 2011; 3: 174-96.
158. Kogan M, Rappaport J. HIV-1 Accessory Protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011; 8: 25.
159. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-61.
160. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-7.
161. Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991; 88: 3195-9.
162. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990; 64: 3097-9.
163. Lai D, Singh SP, Cartas M, et al. Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. FEBS Lett 2000; 469: 191-5.
164. Muller B, Tessmer U, Schubert U, Krausslich HG. Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells. J Virol 2000; 74: 9727.
165. Singh S, Tungaturthi P, Cartas M, et al. Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection or proviral DNA transfection. Virology 2001; 283: 78-83.
166. Camaur D, Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996; 70: 6106-11.
167. Fouchier R, Simon J, Jaffe AB, Malim MH. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol 1996; 70: 8263-9.
168. Welker R, Kottler H, Kalbitzer H, Kräusslich H. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996; 219: 228-36.
169. Kondo E, Mammano F, Cohen EA, Göttlinger H. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 1995; 69: 2759-64.
170. Wu X, Liu H, Xiao H, et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995; 69: 3389-98.
171. Wu X, Liu H, Xiao H, Kappes J. Proteolytic activity of human immunodeficiency virus Vpr-and Vpx-protease fusion proteins. Virology 1996; 219: 307-13.
172. Kobinger GP, Borsetti A, Nie Z, et al. Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 1998; 72: 5441-8.
173. Ao Z, Yu Z, Wang L, Zheng Y, Yao X. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One 2008; 3: e1995.
174. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM. Vpr. A3A chimera inhibits HIV replication. J Biol Chem 2008; 283: 2518-25.
175. Okui N, Sakuma R, Kobayashi N, et al. Packageable antiviral therapeutics against human immunodeficiency virus type 1: viriontargeted virus inactivation by incorporation of a single-chain antibody against viral integrase into progeny virions. Hum Gene Ther 2000; 11: 537-46.
176. BouHamdan M, Kulkosky J, Duan L, Pomerantz R. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies. J Hum Virol 2000; 3: 6-15.
177. Fletcher TM, Soares MA, McPhearson S, et al. Complementation of integrase function in HIV-1 virions. Embo J 1997; 16: 5123-38.
178. Wu X, Liu H, Xiao H, et al. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. Embo J 1997; 16: 5113-22.
179. Liu H, Wu X, Xiao H, Conway JA, Kappes JC. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. J Virol 1997; 71: 7704-10.
180. Wu X, Wakefield JK, Liu H, et al. Development of a novel translentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.
181. Westerman K, Ao Z, Cohen É, Leboulch P. Design of a trans protease lentiviral packaging system that produces high titer virus. Retrovirology 2007; 4: 96.
182. Mitchell RS, Beitzel BF, Schroder ARW, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: e234.
183. Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006; 2: e60.
184. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-306.
185. Lombardo A, Cesana D, Genovese P, et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 2011; 8: 861-9.
186. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475: 217-21.
187. Izmiryan A, Basmaciogullari S, Henry A, Paques F, Danos O. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res 2011; 39: 7610-9.
188. Michel G, Yu Y, Chang T, Yee JK. Site-specific gene insertion mediated by a Cre-loxP-carrying lentiviral vector. Mol Ther 2010; 18: 1814-21.
189. Thyagarajan B, Guimaraes M, Groth A, Calos M. Mammalian genomes contain active recombinase recognition sites. Gene 2000; 244: 47-54.
190. Buchholz F, Stewart AF. Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat Biotechnol 2001; 19: 1047-52.
191. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007; 316: 1912-5.
192. Goujon C, Jarrosson-Wuilleme L, Bernaud J, et al. With a little help from a friend: increasing HIV transduction of monocytederived dendritic cells with virion-like particles of SIVMAC. Gene Ther 2006; 13: 991-4.
193. Berger G, Goujon C, Darlix J, Cimarelli A. SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther 2008; 16: 159-63.
194. Fenard D, Yonemoto W, de Noronha C, et al. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol 2005; 175: 6050-7.
195. Greenberg ME, Bronson S, Lock M, et al. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nefinduced CD4 down-regulation. Embo J 1997; 16: 6964-76.
196. Williams M, Roeth JF, Kasper MR, et al. Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol 2002; 76: 12173-84.
197. D'Aloja P, Olivetta E, Bona R, et al. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants. J Virol 1998; 72: 4308-19.
198. Peretti S, Schiavoni I, Pugliese K, Federico M. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol Ther 2005; 12: 1185-96.
199. Peretti S, Schiavoni I, Pugliese K, Federico M. Selective elimination of HIV-1-infected cells by Env-directed, HIV-1-based viruslike particles. Virology 2006; 345: 115-26.
200. Derdak SV, Kueng HJ, Leb VM, et al. Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci USA 2006; 103: 13144-9.
201. Kueng HJ, Leb VM, Haiderer D, et al. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol 2007; 81: 8666-76.
202. Kueng HJ, Manta C, Haiderer D, et al. Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptorligand interactions. Faseb J 2010; 24: 1572-82.
203. Raymond CS, Soriano P. High-efficiency FLP and C31 sitespecific recombination in mammalian cells. PLoS One 2007; 2: e162.
204. Aoki T, Miyauchi K, Urano E, Ichikawa R, Komano J. Protein transduction by pseudotyped lentivirus-like nanoparticles. Gene Ther 2011; 18: 936-41.
205. Wanisch K, Yáñez-Muñoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17: 1316-32.